• Popular
    • Medicine
    • Radiology
    • Cardiology
    • Surgery
    • Nanomedicine
    • Military Medicine
    • Rehab
  • Categories
    • Exclusive
    • A-D
      • Anesthesiology
      • Art
      • Cardiac Surgery
      • Cardiology
      • Critical Care
      • Dentistry
      • Dermatology
      • Diagnostics
    • E-I
      • Emergency Medicine
      • ENT
      • Genetics
      • Geriatrics
      • GI
      • Informatics
    • M-N
      • Medicine
      • Military Medicine
      • Nanomedicine
      • Net News
      • Neurology
      • Neurosurgery
      • Nuclear Medicine
    • O-P
      • Ob/Gyn
      • Oncology
      • Ophthalmology
      • Orthopedic Surgery
      • Pathology
      • Pediatrics
      • Plastic Surgery
      • Psychiatry
      • Public Health
    • R-V
      • Radiation Oncology
      • Radiology
      • Rehab
      • Reproductive Medicine
      • Space Medicine
      • Sports Medicine
      • Surgery
      • Thoracic Surgery
      • Urology
      • Vascular Surgery
  • SUBSCRIBE
  • Submit PR
  • About
  • Follow
    • Facebook
    • Twitter
    • Linkedin
    • Youtube
    • Instagram
    • RSS
  • Submit PR
  • Log in
Medgadget
Medgadget
  • Popular
    • Medicine
      Etched Nanopillars Kill Bacteria, Fungi on Titanium Implants

      Etched Nanopillars Kill Bacteria, Fungi on Titanium Implants

      Cells Release Insulin in Response to Music

      Cells Release Insulin in Response to Music

      Microneedle Skin Patch Measures Cancer Biomarkers

      Microneedle Skin Patch Measures Cancer Biomarkers

      Enzyme Treatment Strips Mucins from Cancer Cells

      Enzyme Treatment Strips Mucins from Cancer Cells

    • Radiology
      Ultrasound-Equipped Bra Monitors for Breast Cancer

      Ultrasound-Equipped Bra Monitors for Breast Cancer

      Portable and Radiation-Free Imaging with Magnetic Nanoparticles

      Portable and Radiation-Free Imaging with Magnetic Nanoparticles

      Imaging Technique Reveals Living Brain Tissue in its Complexity

      Imaging Technique Reveals Living Brain Tissue in its Complexity

      Wearable Ultrasound for Deep Tissue Monitoring

      Wearable Ultrasound for Deep Tissue Monitoring

    • Cardiology
      Ultrasound-Equipped Bra Monitors for Breast Cancer

      Ultrasound-Equipped Bra Monitors for Breast Cancer

      3D Printed Heart Muscle Beats

      3D Printed Heart Muscle Beats

      Wireless Patch Monitors, Paces Heart and then Biodegrades

      Wireless Patch Monitors, Paces Heart and then Biodegrades

      Photonic Radar Monitors Breathing from a Distance

      Photonic Radar Monitors Breathing from a Distance

    • Surgery
      Growth Factor-Loaded Microparticles Enhance 3D Bioprinted Muscle

      Growth Factor-Loaded Microparticles Enhance 3D Bioprinted Muscle

      Highly Precise Pressure Sensor for Laparoscopic or Robotic Surgical Tools

      Highly Precise Pressure Sensor for Laparoscopic or Robotic Surgical Tools

      Magnetic Tentacle Robots for Minimally Invasive Procedures

      Magnetic Tentacle Robots for Minimally Invasive Procedures

      Artificial Muscle Changes Stiffness with Voltage

      Artificial Muscle Changes Stiffness with Voltage

    • Nanomedicine
      Nanorobots Release Reactive Oxygen Species to Kill Fungal Biofilms

      Nanorobots Release Reactive Oxygen Species to Kill Fungal Biofilms

      Bottlebrush Nanoparticles Deliver Immunostimulatory Drugs

      Bottlebrush Nanoparticles Deliver Immunostimulatory Drugs

      Nanoparticles Deliver mRNA Therapy to the Lungs

      Nanoparticles Deliver mRNA Therapy to the Lungs

      Nanoparticles Get Lymphatic Vessels Pumping

      Nanoparticles Get Lymphatic Vessels Pumping

    • Military Medicine
      Wearable Can Take Multiple Sweat Samples

      Wearable Can Take Multiple Sweat Samples

      Wound Dressing Detects Infection, Changes Color

      Wound Dressing Detects Infection, Changes Color

      Device Measures Hemoglobin More Accurately in Dark Skin

      Device Measures Hemoglobin More Accurately in Dark Skin

      Fingertip Sensor Measures Lithium Levels in Sweat

      Fingertip Sensor Measures Lithium Levels in Sweat

    • Rehab
      Growth Factor-Loaded Microparticles Enhance 3D Bioprinted Muscle

      Growth Factor-Loaded Microparticles Enhance 3D Bioprinted Muscle

      Brain Computer Interface Decodes Speech and Facial Expressions

      Brain Computer Interface Decodes Speech and Facial Expressions

      Semi-Automated Manufacture of E-Skin Sensors

      Semi-Automated Manufacture of E-Skin Sensors

      Above Elbow Amputee Controls Individual Bionic Fingers

      Above Elbow Amputee Controls Individual Bionic Fingers

  • Categories
    • Exclusive
    • A-D
      • Anesthesiology
      • Art
      • Cardiac Surgery
      • Cardiology
      • Critical Care
      • Dentistry
      • Dermatology
      • Diagnostics
    • E-I
      • Emergency Medicine
      • ENT
      • Genetics
      • Geriatrics
      • GI
      • Informatics
    • M-N
      • Medicine
      • Military Medicine
      • Nanomedicine
      • Net News
      • Neurology
      • Neurosurgery
      • Nuclear Medicine
    • O-P
      • Ob/Gyn
      • Oncology
      • Ophthalmology
      • Orthopedic Surgery
      • Pathology
      • Pediatrics
      • Plastic Surgery
      • Psychiatry
      • Public Health
    • R-V
      • Radiation Oncology
      • Radiology
      • Rehab
      • Reproductive Medicine
      • Space Medicine
      • Sports Medicine
      • Surgery
      • Thoracic Surgery
      • Urology
      • Vascular Surgery
  • SUBSCRIBE
  • Submit PR
  • About
  • Log in
  • Submit PR
  • Follow
    • Facebook
    • Twitter
    • Linkedin
    • Youtube
    • Instagram
    • RSS

Peptide Receptor Radionuclide Therapy (PRRT) Market to Surpass US$ 1,598.9 Million at a CAGR of 27.3% by 2028 | Novartis AG (Advanced Accelerator Applications, S.A.)

April 6th, 2022 Coherent Market Insights Releases

Peptide receptor radionuclide therapy (PRRT) is a targeted radionuclide therapy and provides radiation to destroy cancer cells via radiolabeled peptides. There are three types of radiations including β−particles (electrons), α particles, and Auger electrons that are used in the peptide receptor radionuclide therapy (PRRT). Among these radiations, β−particles (electrons) are widely used in PRRT, as it has a long-range to penetrate in target tissues (0.05–12 mm), and neighboring cells around the targeted cell/tissue. Peptide receptor radionuclide therapy (PRRT) is majorly used in the treatment of pancreatic & gastrointestinal tract – neuroendocrine tumors.

*The Download PDF brochure only consist of Table of Content, Research Framework, and Research Methodology.

Request Here For PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/2731

The growing incidence of the pancreatic neuroendocrine tumor and gastrointestinal tract neuroendocrine tumor is expected to drive the market growth over the forecast period. According to the American Society of Clinical Oncology’s (ASCO) 2019 statistics, around 1,000 people are diagnosed with pancreatic neuroendocrine tumors each year in the U.S. and it accounts for 7% of pancreatic cancer cases. According to the same source, the number of patients diagnosed with a pancreatic neuroendocrine tumor has been increasing by around 5% per year in the U.S.

The global peptide receptor radionuclide therapy (PRRT) market was valued at US$ 231.5 million in 2018 and is expected to exhibit a CAGR of 27.3% during the forecast period (2019–2027).

Growing research and development activities, in order to develop novel treatment approach for cancer and regulatory approval for peptide receptor radionuclide therapy, are projected to be major factors driving the growth of the global peptide receptor radionuclide therapy (PRRT) market over the forecast period

Increasing pipeline studies to develop novel radiopeptide therapy is projected to drive the growth of the global peptide receptor radionuclide therapy (PRRT) market over the forecast period. For instance, in May 2018, Merck Sharp & Dome Corp, in collaboration with BTG International Inc., initiated phase II clinical trial on peptide receptor radionuclide therapy for patients with well-differentiated neuroendocrine tumors and symptomatic and/or progressive metastases. The study is expected to be completed by November 2020.

Moreover, increasing approvals of the product by the regulatory authority is projected to drive the growth of the global peptide receptor radionuclide therapy (PRRT) market. For instance, in June 2019, Advanced Accelerator Applications S.A. (AAA), a Novartis company, received State of Israel Ministry of Health approval for its Lutathera, for treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). It is the first PRRT therapy approved in Israel. Lutathera is a lutetium Lu 177-labeled somatostatin analog peptide.

Access research reports that are tailored specifically for you and your organization in order to explore practical growth strategies and recommendations

Buy This Report with Flat USD 2000 Off @ https://www.coherentmarketinsights.com/promo/buynow/2731

High cost associated with cancer treatment is a major factor that is expected to hamper the growth of the market

According to the World Health Organization’s 2018 data, the economic impact of cancer is increasing significantly. The total annual economic cost of cancer treatment in 2010 was estimated at US$ 1.16 trillion, globally. Moreover, till 2018, only one PRRT drug was approved in the U.S. and Europe based on peptide receptor radionuclide therapy (PRRT) and used in the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) including foregut, midgut, and hindgut neuroendocrine tumors in adults. Therefore, the lack of drugs is another major factor restraining the growth of this market. Novartis company’s drug named Lutathera is priced at US$ 47,500 for a full course of treatment, which comprises four infusions (cost for total 4-doses is US$ 190,000). Therefore, such a high cost of drugs is expected to restrain the growth of this market.

Regional Analysis

Based on the region, the global peptide receptor radionuclide therapy (PRRT) market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is projected to hold a dominant position in the market, due to increasing product approval by regional drug regulatory authorities such as the U.S. FDA and Health Canada, to launch the products in the region. For instance, in January 2018, Advanced Accelerator Applications (AAA), a subsidiary of Novartis AG, received the U.S. Food and Drug Administration approval for its Lutetium (177Lu) Oxodotreotide (Lutathera) drug, which is indicated for gastroenteropancreatic neuroendocrine tumor.

Moreover, the Asia Pacific peptide receptor radionuclide therapy (PRRT) market is expected to hold a significant market share over the forecast period, due to the increasing incidence of the neuroendocrine tumor and growing adoption of smart strategies by major manufacturers. For instance, in June 2015, Advanced Accelerator Application, a subsidiary of Novartis AG, entered into a distribution agreement for Lutathera with FUJIFILM RI Pharma, Co., LTD. According to the agreement, FUJIFILM will be marketing and distributing Lutathera in the Japan market.

Novartis AG (Advanced Accelerator Applications, S.A.) is the major player operating in the global peptide receptor radionuclide therapy (PRRT) market.

Detailed Segmentation:

  • Global Peptide Receptor Radionuclide Therapy (PRRT) Market, By Drug Type:
    • Lutetium (Lu-177)-based
  • Global Peptide Receptor Radionuclide Therapy (PRRT) Market, By Disease Indication:
    • Pancreatic – Neuroendocrine Tumor
    • Gastrointestinal Tract – Neuroendocrine Tumor
    • Others
  • Global Peptide Receptor Radionuclide Therapy (PRRT) Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies

Table of Content

Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Peptide Receptor Radionuclide Therapy (PRRT) Market Size Analysis from 2021 to 2028
11.6 COVID-19 Outbreak: Peptide Receptor Radionuclide Therapy (PRRT) Industry Impact

Chapter 2 Global Peptide Receptor Radionuclide Therapy (PRRT) Competition by Types, Applications, and Top Regions and Countries
2.1 Global Peptide Receptor Radionuclide Therapy (PRRT) (Volume and Value) by Type
2.3 Global Peptide Receptor Radionuclide Therapy (PRRT) (Volume and Value) by Regions

Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis

Chapter 4 Global Peptide Receptor Radionuclide Therapy (PRRT) Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America Peptide Receptor Radionuclide Therapy (PRRT) Market Analysis
Chapter 6 East Asia Peptide Receptor Radionuclide Therapy (PRRT) Market Analysis
Chapter 7 Europe Peptide Receptor Radionuclide Therapy (PRRT) Market Analysis
Chapter 8 South Asia Peptide Receptor Radionuclide Therapy (PRRT) Market Analysis
Chapter 9 Southeast Asia Peptide Receptor Radionuclide Therapy (PRRT) Market Analysis
Chapter 10 Middle East Peptide Receptor Radionuclide Therapy (PRRT) Market Analysis
Chapter 11 Africa Peptide Receptor Radionuclide Therapy (PRRT) Market Analysis
Chapter 12 Oceania Peptide Receptor Radionuclide Therapy (PRRT) Market Analysis
Chapter 13 South America Peptide Receptor Radionuclide Therapy (PRRT) Market Analysis
Chapter 14 Company Profiles and Key Figures in Peptide Receptor Radionuclide Therapy (PRRT) Business
Chapter 15 Global Peptide Receptor Radionuclide Therapy (PRRT) Market Forecast (2021-2027)
Chapter 16 Conclusions
Research Methodology

View Press Release: https://www.coherentmarketinsights.com/press-release/peptide-receptor-radionuclide-therapy-prrt-market-2669

About Us:

Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

Sign up and submit a press release

Sponsored

Viral Vector Manufacturing in Gene Therapy and Vaccine Development

Health and Clean Air: Why Indoor Ventilation Matters

Health and Clean Air: Why Indoor Ventilation Matters

New Survey Finds Strong Consumer Preference for More Natural Hernia Repair Options

MedTech Outlook 2023 for Latin America Released

MedTech Outlook 2023 for Latin America Released

Packaging Compliance Labs (PCL) Celebrates Site Expansion in Grand Rapids, MI

interviews & reviews
UV-Free Air Decontamination: Interview with Sorel Rothschild, VP at Quantum Innovations

UV-Free Air Decontamination: Interview with Sorel Rothschild, VP at Quantum Innovations

EarliPoint Evaluation System for ASD Diagnosis: Interview with Tom Ressemann, CEO of EarliTec Dx

EarliPoint Evaluation System for ASD Diagnosis: Interview with Tom Ressemann, CEO of EarliTec Dx

Visually Guided Uterine Biopsies in Physician’s Office: Interview with Allison London Brown, CEO of LUMINELLE

Visually Guided Uterine Biopsies in Physician’s Office: Interview with Allison London Brown, CEO of LUMINELLE

AI-Powered Pain Relief: Interview with Claire Smith, VP at Nevro

AI-Powered Pain Relief: Interview with Claire Smith, VP at Nevro

MISHA Knee Shock Absorber: Interview with Anton Clifford, CEO of Moximed

MISHA Knee Shock Absorber: Interview with Anton Clifford, CEO of Moximed

Shelf-Stable Breast Milk Powder: Interview with Dr. Vansh Langer, CEO at BBy

Shelf-Stable Breast Milk Powder: Interview with Dr. Vansh Langer, CEO at BBy

"We Are Electric" by Sally Adee: Medgadget Interviews the Author

"We Are Electric" by Sally Adee: Medgadget Interviews the Author

  • Subscribe
  • Contact us
  • Submit
  • About
  • Back to top
Medgadget

Medical technologies transform the world! Join us and see the progress in real time. At Medgadget, we report the latest technology news, interview leaders in the field, and file dispatches from medical events around the world since 2004.

  • About
  • Editorial policies
  • Contact
  • Terms of Service
  • Privacy
  • Submit press release
  • Advertise
© Medgadget, Inc. All rights reserved. | The Medical Revolution Will Be Blogged.
Please support this website by adding us to your whitelist in your ad blocker. Ads are what helps us bring you premium content! Thank you!
  • Facebook
  • Twitter
  • LinkedIn
  • Reddit
  • Email